By Dr Emmy Dorothee Grace Fleuren

Journal articles

Lau LMS; Khuong-Quang DA; Mayoh C; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester AK; Fuentes-Bolanos NA; Yeung V; Sullivan A; Omer N; Diamond Y; Jessop S; Battaglia L; Zhukova N; Cui L; Lin A; Gifford AJ; Fleuren EDG; Dalla-Pozza L; Moore AS; Khaw SL; Eisenstat DD; Gottardo NG; Wood PJ; Tapp H; Alvaro F; McCowage G; Nicholls W; Hansford JR; Manoharan N; Kotecha RS; Mateos MK; Lock RB; Tyrrell V; Haber M; Trahair TN; Cowley MJ; Ekert PG; Marshall GM; Ziegler DS, 2024, 'Precision-guided treatment in high-risk pediatric cancers', Nature Medicine, pp. 1 - 10, http://dx.doi.org/10.1038/s41591-024-03044-0

Brown LM; Ekert PG; Fleuren EDG, 2023, 'Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers', Oncogene, 42, pp. 1875 - 1888, http://dx.doi.org/10.1038/s41388-023-02705-7

Fleuren EDG; Vlenterie M; van der Graaf WTA, 2023, 'Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1013359

Van Erp AEM; Hillebrandt-Roeffen MHS; Van Bree NFHN; Plüm TA; Flucke UE; Desar IME; Fleuren EDG; Van Der Graaf WTA; Versleijen-Jonkers YMH, 2022, 'Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma', Sarcoma, 2022, http://dx.doi.org/10.1155/2022/3089424

Fleuren EDG; Terry RL; Meyran D; Omer N; Trapani JA; Haber M; Neeson PJ; Ekert PG, 2021, 'Enhancing the potential of immunotherapy in paediatric sarcomas: Breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors', Biomedicines, 9, pp. 1798, http://dx.doi.org/10.3390/biomedicines9121798

Fordham AM; Ekert PG; Fleuren EDG, 2021, 'Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas', Biochimica et Biophysica Acta - Reviews on Cancer, 1876, http://dx.doi.org/10.1016/j.bbcan.2021.188613

Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG, 2021, 'Chimeric antigen receptor t cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma', Cancers, 13, pp. 4704, http://dx.doi.org/10.3390/cancers13184704

Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O’Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ; O'Brien T; Wong-Erasmus M, 2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4

van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA, 2020, 'Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo', Journal of Cancer Research and Clinical Oncology, 146, pp. 1659 - 1670, http://dx.doi.org/10.1007/s00432-020-03211-z

Holme H; Gulati A; Brough R; Fleuren EDG; Bajrami I; Campbell J; Chong IY; Costa-Cabral S; Elliott R; Fenton T; Frankum J; Jones SE; Menon M; Miller R; Pemberton HN; Postel-Vinay S; Rafiq R; Selfe JL; Von Kriegsheim A; Munoz AG; Rodriguez J; Shipley J; Van Der Graaf WTA; Williamson CT; Ryan CJ; Pettitt S; Ashworth A; Strauss SJ; Lord CJ, 2018, 'Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-29043-z

Holme H; Gulati A; Brough R; Fleuren EDG; Bajrami I; Campbell J; Chong IY; Costa-Cabral S; Elliott R; Fenton T; Frankum J; Jones SE; Menon M; Miller R; Pemberton HN; Postel-Vinay S; Rafiq R; Selfe JL; von Kriegsheim A; Munoz AG; Rodriguez J; Shipley J; van der Graaf WTA; Williamson CT; Ryan CJ; Pettitt S; Ashworth A; Strauss SJ; Lord CJ, 2018, 'Erratum to: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (Scientific Reports, (2018), 8, 1, (10614), 10.1038/s41598-018-29043-z)', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-30922-8

Van Erp AEM; Versleijen-Jonkers YMH; Van Der Graaf WTA; Fleuren EDG, 2018, 'Targeted therapy-based combination treatment in rhabdomyosarcoma', Molecular Cancer Therapeutics, 17, pp. 1365 - 1380, http://dx.doi.org/10.1158/1535-7163.MCT-17-1131

Desar IME; Fleuren EDG; van der Graaf WTA, 2018, 'Systemic Treatment for Adults with Synovial Sarcoma', Current Treatment Options in Oncology, 19, http://dx.doi.org/10.1007/s11864-018-0525-1

Brandsma I; Fleuren EDG; Williamson CT; Lord CJ, 2017, 'Directing the use of DDR kinase inhibitors in cancer treatment', Expert Opinion on Investigational Drugs, 26, pp. 1341 - 1355, http://dx.doi.org/10.1080/13543784.2017.1389895

van Erp AEM; Hillebrandt-Roeffen MHS; van Houdt L; Fleuren EDG; van der Graaf WTA; Versleijen-Jonkers YMH, 2017, 'Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib', Targeted Oncology, 12, pp. 815 - 826, http://dx.doi.org/10.1007/s11523-017-0528-z

Fleuren EDG; Vlenterie M; Van Der Graaf WTA; Hillebrandt-Roeffen MHS; Blackburn J; Ma X; Chan H; Magias MC; Van Erp A; Van Houdt L; Cebeci SAS; Van De Ven A; Flucke UE; Heyer EE; Thomas DM; Lord CJ; Marini KD; Vaghjiani V; Mercer TR; Cain JE; Wu J; Versleijen-Jonkers YMH; Daly RJ, 2017, 'Phosphoproteomic profiling reveals ALK and MET as novel actionable targets across synovial sarcoma subtypes', Cancer Research, 77, pp. 4279 - 4292, http://dx.doi.org/10.1158/0008-5472.CAN-16-2550

Jones SE; Fleuren EDG; Frankum J; Konde A; Williamson CT; Krastev DB; Pemberton HN; Campbell J; Gulati A; Elliott R; Menon M; Selfe JL; Brough R; Pettitt SJ; Niedzwiedz W; Van Der Graaf WTA; Shipley J; Ashworth A; Lord CJ, 2017, 'ATR Is a therapeutic target in synovial sarcoma', Cancer Research, 77, pp. 7014 - 7026, http://dx.doi.org/10.1158/0008-5472.CAN-17-2056

Vlenterie M; Hillebrandt-Roeffen MHS; Schaars EWM; Flucke UE; Fleuren EDG; Navis AC; Leenders WPJ; Versleijen-Jonkers YMH; van der Graaf WTA, 2016, 'Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients', Annals of Surgical Oncology, 23, pp. 2745 - 2752, http://dx.doi.org/10.1245/s10434-016-5341-x

Kager L; Whelan J; Dirksen U; Hassan B; Anninga J; Bennister L; Bovee JVMG; Brennan B; Broto JM; Brugieres L; Cleton-Jansen A-M; Copland C; Dutour A; Fagioli F; Ferrari S; Fiocco M; Fleuren E; Gaspar N; Gelderblom H; Gerrand C; Gerss J; Gonzato O; van der Graaf W; Hecker-Nolting S; Herrero-Martin D; Klco-Brosius S; Kovar H; Ladenstein R; Lancia C; LeDeley M-C; McCabe MG; Metzler M; Myklebost O; Nathrath M; Picci P; Potratz J; Redini F; Richter GHS; Reinke D; Rutkowski P; Scotlandi K; Strauss S; Thomas D; Tirado OM; Tirode F; Vassal G; Bielack SS, 2016, 'The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report', CLINICAL SARCOMA RESEARCH, 6, http://dx.doi.org/10.1186/s13569-016-0043-5

Fleuren EDG; Zhang L; Wu J; Daly RJ, 2016, 'The kinome 'at large' in cancer', Nature Reviews Cancer, 16, pp. 83 - 98, http://dx.doi.org/10.1038/nrc.2015.18

Fleuren EDG; Versleijen-Jonkers YMH; Roeffen MHS; Franssen GM; Flucke UE; Houghton PJ; Oyen WJG; Boerman OC; Van Der Graaf WTA, 2014, 'Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models', International Journal of Cancer, 135, pp. 2770 - 2782, http://dx.doi.org/10.1002/ijc.28933

Fleuren EDG; Versleijen-Jonkers YMH; Heskamp S; van Herpen CML; Oyen WJG; van der Graaf WTA; Boerman OC, 2014, 'Theranostic applications of antibodies in oncology', Molecular Oncology, 8, pp. 799 - 812, http://dx.doi.org/10.1016/j.molonc.2014.03.010

Fleuren EDG; Versleijen-Jonkers YMH; Boerman OC; van der Graaf WTA, 2014, 'Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives', Biochimica et Biophysica Acta - Reviews on Cancer, 1845, pp. 266 - 276, http://dx.doi.org/10.1016/j.bbcan.2014.02.005

Fleuren EDG; Hillebrandt-Roeffen MHS; Flucke UE; te Loo DMWM; Boerman OC; van der Graaf WTA; Versleijen-Jonkers YMH, 2014, 'The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma', Oncotarget, 5, pp. 12753 - 12768, http://dx.doi.org/10.18632/oncotarget.2648

Fleuren EDG; van der Graaf WTA; Roeffen MHS; Flucke UE; Schreuder B; Boerman O; Versleijen-Jonkers YMH, 2014, 'The Role of Axl in Ewing Sarcoma', Annals of Oncology, 25, pp. iv508 - iv508, http://dx.doi.org/10.1093/annonc/mdu354.45

Fleuren EDG; Versleijen-Jonkers YMH; Heskamp S; Roeffen MHS; Bouwman WH; Molkenboer-Kuenen JDM; Van Laarhoven HWM; Oyen WJG; Boerman OC; Van Der Graaf WTA, 2013, 'The strength of small: Improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(ab′)2-R1507 fragments in Ewing sarcomas', European Journal of Cancer, 49, pp. 2851 - 2858, http://dx.doi.org/10.1016/j.ejca.2013.04.009

Fleuren EDG; Roeffen MHS; Leenders WP; Flucke UE; Vlenterie M; Schreuder HW; Boerman OC; Van Der Graaf WTA; Versleijen-Jonkers YMH, 2013, 'Expression and clinical relevance of MET and ALK in Ewing sarcomas', International Journal of Cancer, 133, pp. 427 - 436, http://dx.doi.org/10.1002/ijc.28047

Fleuren EDG; Versleijen-Jonkers YMH; Van De Luijtgaarden ACM; Molkenboer-Kuenen JDM; Heskamp S; Roeffen MHS; Van Laarhoven HWM; Houghton PJ; Oyen WJG; Boerman OC; Van Der Graaf WTA, 2011, 'Predicting IGF-1R therapy response in bone sarcomas: Immuno-SPECT imaging with radiolabeled R1507', Clinical Cancer Research, 17, pp. 7693 - 7703, http://dx.doi.org/10.1158/1078-0432.CCR-11-1488

Fleuren E; O'Toole S; Millar E; Mcneil CM; Lopez-Knowles E; Boulghourjian A; Croucher DR; Schramek D; Brummer T; Penninger JM; Sutherland RL; Daly RJ, 2010, 'Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development', International Journal of Cancer, 127, pp. 1486 - 1492

Brummer T; Larance M; Abreu MTH; Lyons RJ; Timpson P; Emmerich CH; Fleuren EDG; Lehrbach GM; Schramek D; Guilhaus M; James DE; Daly RJ, 2009, 'The docking protein and proto-oncogene product Gab2 is regulated via a novel negative feedback mechanism mediated by 14-3-3 binding.', Cell communication and signaling : CCS, 7, pp. A12 - A12, http://dx.doi.org/10.1186/1478-811X-7-S1-A12

Brummer T; Larance MC; Abreu M; Lyons RJ; Timpson P; Emmerich C; Fleuren E; Lehrbach GM; Schramek D; Guilhaus M; James DE; Daly RJ, 2008, 'Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein', European Molecular Biology Organization, 27, pp. 2305 - 2316

Conference Papers

Volken L; Tax G; Mao J; Cadiz R; Rishfi M; Dolman E; Fleuren E, 2024, 'Advancing precision medicine in paediatric sarcoma: Harnessing DNA damage response pathway for targeted therapies.', Sydney, presented at ZERO Childhood Cancer National Symposium 2024, Sydney, 08 May 2024

Perkins C; Barger Z; Fordham A; Salib A; Lim Kam Sian T; Daly R; Ekert P; Fleuren E, 2024, 'Phosphoproteomic profiling for novel target identification in childhood sarcomas: Paving the road towards improved outcomes for relapsed and metastatic osteosarcoma', Sydney, Australia, presented at ZERO Childhood Cancer National Symposium “Precision in Action: Collaboration Driving Cancer Breakthroughs”, Sydney, Australia, 08 May 2024

Barger Z; Fordham A; Mao J; Brown L; Perkins C; Gunther K; Paul E; Fleuren E, 2024, 'ZERO and beyond: Establishment, Characterisation, and Utilisation of Nine Novel Patient-Derived Osteosarcoma Cell Lines', Sydney, Australia, presented at ZERO Childhood Cancer National Symposium “Precision in Action: Collaboration Driving Cancer Breakthroughs", Sydney, Australia, 08 May 2024

Volken L; Tax G; Mao J; Cadiz R; Rishfi M; Dolman E; Fleuren E, 2024, 'Exploiting the dna damage response to develop personalised treatments for high-risk sarcoma in children', Lorne, presented at Lorne Cancer, Lorne, 09 February 2024, https://cancer-2024.p.asnevents.com.au/days/2024-02-09/abstract/100289

Perkins C; Barger Z; Fordham A; Salib A; Lim Kam Sian T; Daly R; Ekert P; Fleuren E, 2024, 'Phosphoproteomic profiling for novel target identification in childhood sarcomas: Paving the road towards improved outcomes for relapsed and metastatic osteosarcoma.', Lorne, presented at Lorne Cancer, Lorne, 09 February 2024, https://cancer-2024.p.asnevents.com.au/days/2024-02-09/abstract/100264

Perkins C; Barger Z; Fordham A; Salib A; Lim Kam Sian T; Daly R; Ekert P; Fleuren E, 2023, 'Phosphoproteomic profiling for novel target identification in childhood sarcomas: Paving the road towards improved outcomes for relapsed and metastatic osteosarcoma', Sydney, presented at Children’s Cancer Institute - Research Symposium, Sydney, 04 December 2023

Barger Z; Fordham A; Mao J; Brown L; Perkins C; Gunther K; Ekert P; Fleuren E, 2023, 'Advancing Preclinical Sarcoma Models: The Establishment and Characterisation of Nine Novel Patient-Derived Osteosarcoma Cell Lines', Melbourne, presented at Australia and New Zealand Sarcoma Association (ANZSA) Annual Scientific Meeting, Melbourne, 10 November 2023

Perkins C; Barger Z; Fordham A; Salib A; Lim Kam Sian T; Daly R; Ekert P; Fleuren E, 2023, 'Phosphoproteomic profiling for novel target identification in childhood sarcomas: Paving the road towards improved outcomes for relapsed and metastatic osteosarcoma', Melbourne, presented at Australia and New Zealand Sarcoma Association (ANZSA) Annual Meeting, Melbourne, 10 November 2023

Perkins C; Barger Z; Fordham A; Salib A; Lim Kam Sian T; Daly R; Ekert P; Fleuren E, 2023, 'Phosphoproteomic profiling for novel target identification in childhood sarcomas: Paving the road towards improved outcomes for relapsed and metastatic osteosarcoma.', Cape Schanck/Melbourne, presented at Cell Signalling and its Therapeutic Implications (CSTI) 2023, Cape Schanck/Melbourne, 16 May 2023, https://drive.google.com/file/d/1G0HeWsknc2z2W3Tq0rTQkECg4SLzgTsO/view

Perkins C; Barger Z; Fordham A; Salib A; Lim Kam Sian T; Daly R; Ekert P; Fleuren E, 2023, 'Phosphoproteomic profiling for novel target identification in childhood sarcomas: Paving the road towards improved outcomes for relapsed and metastatic osteosarcoma', Melbourne (Cape Schanck), presented at Cell Signalling and its Therapeutic Implications (CSTI 2023), Melbourne (Cape Schanck), 15 May 2023, https://drive.google.com/file/d/1G0HeWsknc2z2W3Tq0rTQkECg4SLzgTsO/view

Xie J; Gifford A; Mao J; Cadiz R; Avila A; Yun DY; Zhou A; Dolman E; Fleuren E; Mayoh C; Barahona P; Lau L; Kamili A; Tsoli M; Marshall G; Ziegler D; Trahair T; Haber M; Tyrrell V; Lock R, 2022, 'Establishment and application of patient-derived xenograft models for personalised medicine in paediatric cancer', Sydney, presented at Children’s Cancer Institute - Research Symposium 2022, Sydney, 06 December 2022

Barger Z; Fordham A; Perkins C; Gunther K; Ekert P; Fleuren E, 2022, 'Optimisation of functional in vitro patient-derived osteosarcoma cell culture models', Sydney, presented at Children’s Cancer Institute - Research Symposium 2022, Sydney, 06 December 2022

Fordham A; Brown L; Mayoh C; Wong M; Barger Z; O'Regan L; Lim Kan Siam T; Xie J; Gunther K; Barahona P; Ajuyah P; Lau L; Ziegler D; Haber M; Tyrrell V; Lock R; Cowley M; Nicholls W; Daly R; Ekert P; Fleuren E, 2022, 'MULTI-PLATFORM TYROSINE KINASE PROFILING REVEALS NOVEL ACTIONABLE FGFR ABERRATIONS ACROSS PEDIATRIC AND ADOLESCENT AND YOUNG ADULT SARCOMAS', Vancouver, Canada, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting 2022, Vancouver, Canada, 17 November 2022

Barger Z; Fordham A; Perkins C; Gunther K; Ekert P; Fleuren E, 2022, 'Optimisation of functional in vitro patient-derived osteosarcoma cell culture models.', Sydney, presented at ZERO Childhood Cancer National Symposium “Towards Precision Oncology for All” 2022, Sydney, 26 October 2022

Fordham A; Brown L; Mayoh C; Wong M; Barger Z; Xie J; Gunther K; Trebilcock P; Lock R; Cowley M; Ekert P; Fleuren E, 2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma', Sydney (virtual), presented at Kids Cancer Alliance (KCA) Symposium 2021, Sydney (virtual), 02 September 2021

Fleuren E; Dolman E; Lau L; Xie J; Batey D; Mayoh C; Barahona P; Khuong Quang DA; Wong M; ZERO PDTT; ZERO OT; Norris M; Haber M; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Lock R; Ekert P, 2021, 'Supporting clinical decision-making for PI3K/AKT/mTOR inhibitors for high-risk paediatric and adolescent and young adult (AYA) sarcoma', Virtual, presented at The Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Annual Scientific Meeting, Virtual, 24 June 2021

Fordham A; Brown L; Mayoh C; Wong M; Barger Z; Xie J; Gunther K; Trebilcock P; Lim Kam Sian T; Lock R; Daly R; Cowley M; Ekert P; Fleuren E, 2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma.', Virtual, presented at The Australian Society for Medical Research (ASMR) 2021, Virtual, 10 June 2021

Fleuren E; Dolman E; Lau L; Xie J; Batey D; Mayoh C; Barahona P; Sherstyuk A; Khuong Quang DA; Wong M; ZERO PDTT; ZERO OT; Thomas D; Mould E; Norris M; Haber M; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Lock R; Ekert P, 2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric and AYA sarcoma', Virtual, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting 2020, Virtual, 18 November 2020

Fleuren E; Dolman E; Lau L; Xie J; Batey D; Mayoh C; Barahona P; Khuong Quang DA; Wong M; ZERO PDTT; ZERO OT; Norris M; Haber M; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Lock R; Ekert P, 2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric sarcoma patients', Virtual, presented at KCA Symposium 2020, Virtual, 17 September 2020

Back to profile page